Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033644 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00033644: Clinical Trial Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00033644 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033644, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent cancer of the uterus.
Interventions
- DRUG cisplatin
- DRUG dacarbazine
- DRUG doxorubicin hydrochloride
- BIOLOGICAL sargramostim
- DRUG mitomycin C
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Phase | Phase 2 |
Why NCT00033644 stopped before completion
NCT00033644 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00033644 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00033644 about?
NCT00033644 is a clinical study titled "Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from ...
What is the current status of trial NCT00033644?
This trial is currently terminated. It is a Phase 2 study. The study started on 2002-03.
What interventions are being tested in trial NCT00033644?
The interventions under investigation include: cisplatin (DRUG), dacarbazine (DRUG), doxorubicin hydrochloride (DRUG), sargramostim (BIOLOGICAL), mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00033644?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia